Responses
Poster Presentations
02. Tumor microenvironment and microbiome in immunotherapy
P02.07 Trial in progress: anti-PD1, capecitabine, and oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study (AuspiCiOus)
Compose a Response to This Article
Other responses
No responses have been published for this article.
